Iowa Impact!

Medical Innovation Summit

Friday, August 26, 2011 |

John Orloff, M.D.

8:00 AM Registration |

FFA Center, Des Moines Area Communit

Chief Medical Officer & Senior Vice President, Global Development, Novartis Pharma AG
Dr. John Orloff is the Chief Medical Officer and Senior Vice President, Global Development, for Novartis Pharma AG. In this position, Dr. Orloff is responsible for providing strategic and scientific leadership for all processes within Global Development, ensuring that all functions adhere to quality standards and comply with regulatory requirements, while driving functional excellence and innovation to support business needs. In addition, Dr. Orloff serves as Chair of the Pharma Portfolio Stewardship Board (PSB), which oversees safety and risk management plans for products within Pharma, and has responsibility for representing Novartis externally in various forums interfacing with the scientific, academic, and health policy communities. Before assuming his current position, Dr. Orloff was Head of US Medical and Drug Regulatory Affairs, North America. Throughout his tenure at Novartis, Dr. Orloff has held a number of roles with increasing responsibility, including Section Head for Bone Metabolism in Clinical Development, Vice President and Therapeutic Area Head of the Arthritis, Bone Metabolism, and Womens Health division within Clinical Development and Medical Affairs, and Global Head of Regulatory Strategy. He also led a cross-functional, development-wide effort at Novartis Pharma to reshape the drug development process, from discovery to the post-marketing arena. Dr. Orloff came to Novartis in April 2003, following his departure from Merck, where he held positions since 1997. At Merck, he was responsible for clinical development of new compounds for osteoporosis and bonerelated conditions, including the once-weekly alendronate clinical program, and served on the business strategy team. Dr. Orloff served on the faculty of Yale University for eight years, where he was an associate professor. He currently serves as a clinical associate professor at the Robert Wood Johnson Medical School in New Brunswick, N.J. Novartis Pharmaceuticals Corportation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The companys mission is to improve peoples lives by pioneering novel healthcare solutions. Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS) which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines; cost-saving generic pharmaceuticals; preventive vaccines; diagnostic tools; and consumer health products. Novartis is the only company with leading positions in these areas. Novartis has annual sales exceeding $45 billion and is headquartered in Basel, Switzerland. Novartis Group companies employ approximately 97,000 full-time associates and operate in over 140 countries around the world

Orloff.indd 1

8/22/11 4:57 PM